Tecentriq Hybreza™
Understanding Tecentriq Hybreza™
Tecentriq Hybreza™ is a combination of the immunotherapy drug atezolizumab and the enzyme hyaluronidase-tqjs. This innovative formulation enables subcutaneous (under-the-skin) injection for the treatment of various cancers in adults. Tecentriq Hybreza™ offers a more convenient and time-efficient option for patients who require atezolizumab therapy, without compromising the drug’s efficacy.
How Tecentriq Hybreza™ Works:
- Blocks PD-L1, a protein that helps cancer cells evade the immune system
- Enhances T-cell activation, allowing the immune system to target and destroy cancer cells
- Offers a subcutaneous injection option, reducing infusion time and improving treatment convenience
FDA Approval:
- Tecentriq Hybreza™: Approved on September 12, 2024, for all adult indications previously approved for intravenous (IV) Tecentriq.
For more information, please visit the Tecentriq Hybreza™ patient website and speak with your healthcare provider to determine if Tecentriq Hybreza™ is the right treatment option for you.
Referral Form: |
MANUFACTURER: Genentech (a subsidiary of Roche) |
CLASS: PD-L1 inhibitor (immune checkpoint inhibitor) |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: Subcutaneous Injection |
|
FREQUENCY: Every 2, 3, or 4 weeks, depending on condition |
Length of infusion: 60 mins |
FOR MORE INFORMATION: |
Related drugs
